Abstract
Multicenter prospective non-comparative open-label clinical study to assess clinical and microbiological efficacy and safety of josamycin (16-memebered macrolide) in adults with non-severe community-acquired pneumonia (CAP) was performed. Patients who met all the inclusion/exclusion criteria were given 0.5 g of josamycin t.i.d (withor without food). A total of 88 ambulatory and hospitalized patients (mean age was 45.5±13.7 years) with non-severe CAP and associated low/medium risk for poor outcome were included. The mean duration of antimicrobial therapy was 7.8±1.4 days. Clinical efficacy of josamycin was reported in 92.8% of cases. Patients receiving josamycin experienced rapid resolution of clinical symptoms and defervescence. Microbiological cure rate (eradication and probable eradication) was 85.7%. Adverse events (gastrointestinal) possibly related to josamycin were reported in 8% of patients. All adverse events were mild and transient; the only 1 case of therapy discontinuation due to an adverse event was reported. Josamycin was well tolerated in 98.9% of patients.
-
1.
Чучалин А.Г. Пульмонология. Белая книга. Москва; 2003.
-
2.
Ноников В.Е. Диагностика и лечение атипичных пневмоний. Consilium Medium 2001; 3(3):138-140.
-
3.
Зубков М.Н., Стецюк О.У., Козлов Р.С., Страчунский Л. С. Этиология и микробиологическая диагностика внебольничных пневмоний. В кн.: Пневмония. Под ред. Чучалина А.Г., Синопальникова А.И., Чернеховской Н.Е. Москва: Экономика и информатика; 2002.
-
4.
Bartlett J.G., Dowell S.F., Mandell L.A., et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-82.
-
5.
British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56(Suppl. IV):1-64.
-
6.
Mandell L.A., Bartlett J.G., Dowell S.F., et al. Update of practice guidelines for the management of communityacquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
-
7.
Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Москва; 2006.
-
8.
Bryskier A., Butzler J.-P. Macrolides. In: Finch R.G., Greenwood D., Norrby S.R., Whitley R.J., editors. Antibiotic and Chemotherapy. Anti-infective agents and their use in therapy. Churchill Livingstone, 8th Ed., 2003, p. 310-325.
-
9.
Stahl J.E., Barza M., DesJaidin J., et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576-80.
-
10.
Martinez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-95.
-
11.
Синопальников А.И. Новые горизонты применения макролидов при инфекциях дыхательных путей. Материалы XIV конгресса ECCMID. Российские медицинские вести 2004; 9(2):16-22.
-
12.
Попкова А.М., Верткин А.Л., Колобова С.В. Макролиды (монография). Москва; 2000.
-
13.
Sauermann R., Gattringer R., Graninger W., et al. Phenotypes of macrolide resistance of group A streptococci isolates from outpatients in Bavaria and susceptibility to 16 antibiotics. J Antimicrob Chemother 2003; 51:53-7.
-
14.
Buxbaum A., Forsthuber S., Graninger W., et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumonia in Austria. J Antimicrob Chemother 2004; 54:247-50.
-
15.
Giovanetti E., Brensiani A., Burioni R., et al. A novel efflux system in inducibely erythromycin-resistant strains of Streptococcus pyogenes. Antimicrob Agents Chemother 2002; 46:3750-5.
-
16.
Nicaido H., Zgurskaya H.I. Antibiotic efflux mechanism. Curr Opinion Infect Dis 1999; 12:529-36.
-
17.
Tait-Kamradt A., Davies T., Appelbaum P. Two new mechanism of macrolide resistance in clinical strains of Streptococus pneumonia from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395-401.
-
18.
Klugman K. Capper T., Widdowson C., et al. Increased activity of 16-membered lactone ring macrolides against erythromycin resistant Streptococcus pyogenes and Streptococcus pneumonia: characterization of South African isolates. J Antimicrob Chemother 1998; 42:729-34.
-
19.
Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Clinical Microbiology and Antimicrobial Chemotherapy.2006; 8(1):33-47.
-
20.
Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич; 1998.
-
21.
Privitera G., Bonino S., Del Mastro S. Clinical multicentre trial with josamycin propionate in paediatric patients. Int J Clin Pharmacol Res 1984; 4:201-7.
-
22.
Performance standards for antimicrobial susceptibility testing. Eighth informational supplement. NCCLS Document M 100-S8. West Valley Road, Wayne. Pennsylvania; 1998.
-
23.
Европейское руководство по клинической оценке противоинфекционных лекарственных средств. Под ред. Beam T.R. Jr., Gilbert D.N., Kunin C.M. Смоленск: Амипресс; 1996.
-
24.
Mensa J., Trilla A., Tarello I., et al. Treatment of atypical pneumonia with josamycin. Med Clin (Barc) 1989; 92:285-87.
-
25.
Gendrel D., Raymond J., Moulin F., et al. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur J Clin Microbiol Infect Dis 1997; 16:388-91.
-
26.
Mensa J., Trilla A., Moreno A., et al. Five-day treatment of non severe community-acquired pneumonia with josamycin. J Antimicrob Chemother 1993; 31:749-54.
-
27.
Straneo J., Scarpazza G. Efficacy and safety of clarithromycin versus josamycin in the treatment of hospitalized patients with bacterial pneumonia. J Int Med Res 1990; 18:164-70.
-
28.
Lozano R., Balaguer A. Josamycin in the treatment of bronchopulmonary infections. Clin Ther 1991; 13:181- 288.